Subscribe To
Why alnylam pharmaceuticals topped the market today
The biotech is a foot soldier in the war against alzheimer's disease. It published encouraging interim ...
July 17, 2023, 6:29 pm
Eli lilly & co study shows alzheimer's drug slows memory decline
Eli Lilly & Co revealed on Monday final results from its Phase 3 clinical study of donanemab at the alzheimer<...
July 17, 2023, 1:13 pm
Eli lilly says alzheimer's treatment slows cognitive decline
A Phase 3 trial shows that Eli Lilly's investigational alzheimer's treatment donanemab significantly sl...
July 17, 2023, 11:00 am
Eli lilly expects fda decision on alzheimer's treatment donanemab by the end of the year
Eli Lilly is racing to market donanemab for alzheimer's after Eisai and Biogen's drug for the disease, ...
July 17, 2023, 10:15 am
Eli lilly's alzheimer's treatment shows promise in early stages of disease — but safety concerns remain
The Eli Lilly and Co. LLY, -0.47% investigational alzheimer's treatment donanemab has shown particular ...
July 17, 2023, 10:15 am
Lilly drug slows alzheimer's by 60% for mildly impaired patients, alzheimer's group says
Eli Lilly's experimental drug donanemab slowed the progression of alzheimer's by 60% for patients in th...
July 17, 2023, 10:08 am
Biovie's clinical dementia drug ne3107 shown to reduce dna methylation
BioVie Inc (NASDAQ:BIVI) presented a poster over the weekend showcasing the epigenetic basis for how its drug candidate NE3107 may have regulated spec...
July 17, 2023, 9:09 am
Why isn't biogen stock soaring after this major fda approval?
The FDA gave full approval for alzheimer's drug Leqembi in July. Despite the positive news, Biogen's st...
July 13, 2023, 8:15 am
Eisai to present the latest alzheimer's disease pipeline and research, including lecanemab and anti-mtbr tau antibody e2814, at the alzheimer's association international conference (aaic) 2023
TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the...
July 11, 2023, 7:30 pm
Prothena (prta) alzheimer's disease drug licensed by bmy
Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment ...
July 11, 2023, 10:17 am
Eisai exec who helped steer alzheimer's drug approval to retire in july
The Eisai executive who helped garner full U.S. approval for the Japanese drugmaker's alzheimer's disea...
July 11, 2023, 3:18 am
Leqembi approval offers renewed hope for novel alzheimer's disease treatments
US officials have granted full approval to Leqembi, the first medication to demonstrate modest effectiveness in slowing cognitive decline associated w...
July 10, 2023, 4:43 pm
Quanterix (qtrx) advances in alzheimer's diagnosis with lucentad
Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with ...
July 10, 2023, 12:30 pm
Biogen (biib) stock down despite fda nod to alzheimer's drug
Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of alzheimer's ...
July 10, 2023, 12:30 pm
Biogen shares ‘an under-owned turnaround story,' jefferies analysts say
Shares of Biogen Inc. BIIB, -3.48%, which last week received a milestone U.S. Food and Drug Administration approval for ...
July 10, 2023, 8:58 am
Fda approves new alzheimer's drug but creators biogen and eisai stock slides
Eisai saw its stock fall 4.67% on the news and Biogen was down 2.07%....
July 10, 2023, 8:00 am
Biogen shares fall after fda approval of alzheimer's drug leqembi
Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. NASDAQ: BIIB swooned 2.88% in heavy...
July 10, 2023, 7:11 am
Biogen and alzheimer's disease: too early to celebrate
The FDA has granted full approval to Biogen and Eisai's anti-amyloid antibody drug Leqembi, but there is skepticism about its efficacy and safety. The...
July 9, 2023, 11:52 pm
Medicare will pay for alzheimer's drug leqembi. what patients and doctors should know
Patients with early alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leq...
July 8, 2023, 7:00 am
Sales of alzheimer's drug leqembi may be slow initially but could pick up in 2024
Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term....
July 7, 2023, 1:59 pm